Content about Antiarrhythmic agents

January 17, 2014

Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets. 

According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million. 

January 4, 2011

Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.

Par announced the shipment of propafenone SR capsules, a treatment for atrial fibrillation in patients without structural heart disease.

The drug is a generic version of GlaxoSmithKline’s Rhythmol SR, which has annual sales of around $121 million, according to IMS Health.

September 20, 2010

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

RIDGEFIELD, Conn. A Food and Drug Administration advisory committee has recommended approval of a drug for patients with atrial fibrillation.

 

The FDA cardiovascular and renal drugs advisory committee voted unanimously to recommend approval for Boehringer Ingelheim's Pradaxa (dabigatran etexilate), for preventing strokes in atrial fibrillation patients. For the last 50 years, warfarin has been the only oral anticoagulant drug available for this purpose.

 

 

July 6, 2010

Launch and use of new heart drugs will drive the market for drugs to treat...

May 13, 2010

An investigational drug for treating a common form of abnormal heart rhythm works better than...